Ozempic
- Product NDC
- 0169-1310
- 11-digit product format
- 001691310
- Labeler code
- 0169
- Product ID
- 0169-1310_852fff2d-704e-4b01-9244-439a28094202
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- semaglutide
- Dosage form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Labeler
- Novo Nordisk Pharmaceutical Industries, LP
- Application
- NDA209637
- Marketing category
- NDA
- Marketing start
- 2022-10-07
- Substance
- SEMAGLUTIDE
- Active strength
- 1 mg/.5mL
- Pharmacologic classes
- GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Related UNII Ingredients
| UNII | Preferred term | Registry number | Matched term |
|---|
| 53AXN4NNHX | SEMAGLUTIDE | 910463-68-2 | SEMAGLUTIDE |
Related DailyMed Labels
| Title | Manufacturer | Effective date | Type | Version |
|---|
| Ozempic | Novo Nordisk Pharmaceutical Industries, LP | 2026-05-19 | HUMAN PRESCRIPTION DRUG LABEL | 19 |
| Ozempic | Novo Nordisk | Novo Nordisk A/S | Novo Nordisk Pharmaceutical Industries, LP | 2025-01-02 | HUMAN PRESCRIPTION DRUG LABEL | 16 |